MedElevator Войти в исследования
← Поиск публикаций

DOI 10.2337/db25-0711

Медицинская библиотека · Oncology (Williston Park, N.Y.) · 2004

Advising women at high risk of breast cancer.

Triolo Taylor M, Sosenko Jay M, Cuthbertson David, Oram Richard A, Parikh Hemang M, Steck Andrea K, Sims Emily K, Jacobsen Laura M, Nathan Brandon, Templeman Erin L, Onengut-Gumuscu Suna, Evans-Molina Carmella, Rich Stephen S, Atkinson Mark A, Redondo Maria J, Type 1 Diabetes TrialNet Study Group*

СтатьяПеревод в очереди

Аннотация

UNLABELLED: Insulin secretion varies widely in preclinical type 1 diabetes. To understand the pathogenesis of this metabolic heterogeneity, we asked whether genetic predisposition to type 2 diabetes, quantified by a type 2 diabetes genetic risk score (T2D-GRS), modulates β-cell function and disease progression in individuals at risk of type 1 diabetes. We analyzed 4,324 islet autoantibody–positive TrialNet Pathway to Prevention participants with genome-wide genotyping and oral glucose tolerance testing. Both T2D-GRS and the type 1 diabetes genetic risk score 2 (T1D-GRS2) differed significantly across five previously described groups defined by C-peptide area under the curve (AUC; a measure of insulin secretion). The highest C-peptide AUC group, compared with the lowest, had significantly higher T2D-GRS, lower T1D-GRS2, higher BMI z-score, greater insulin resistance, older age, and lower prevalence of male participants; multiple islet autoantibody positivity; and IA-2 or insulin autoantibody positivity. Progression to clinical (stage 3) type 1 diabetes was significantly associated with T1D-GRS2 across all groups and with T2D-GRS in all but the lowest C-peptide AUC group. In conclusion, type 2 diabetes genetic burden shapes metabolic heterogeneity and accelerates progression in preclinical type 1 diabetes. These results support the evaluation of type 2 diabetes–related mechanisms as targets to improve the prediction and prevention of type 1 diabetes.

ARTICLE HIGHLIGHTS: Heterogeneity in β-cell function is a barrier to precision medicine in type 1 diabetes. We asked whether type 2 diabetes-associated genes influence insulin secretion and progression to clinical type 1 diabetes in autoantibody-positive individuals. A type 2 diabetes genetic risk score was associated with higher C-peptide area under the curve (AUC) and increased clinical type 1 diabetes risk in all but the lowest C-peptide AUC subgroup. Addressing type 2 diabetes mechanisms could improve type 1 diabetes prediction and prevention.

Для цитирования: Triolo Taylor M, Sosenko Jay M, Cuthbertson David, Oram Richard A, Parikh Hemang M, Steck Andrea K, Sims Emily K, Jacobsen Laura M, Nathan Brandon, Templeman Erin L, Onengut-Gumuscu Suna, Evans-Molina Carmella, Rich Stephen S, Atkinson Mark A, Redondo Maria J, Type 1 Diabetes TrialNet Study Group*. Advising women at high risk of breast cancer.. Oncology (Williston Park, N.Y.). 2004. DOI: 10.2337/db25-0711.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.